Precision Biosciences (DTIL) Net Equity Issued and Repurchased (2021 - 2023)

Precision Biosciences (DTIL) has 3 years of Net Equity Issued and Repurchased data on file, last reported at $2.8 million in Q4 2023.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $2.8 million in Q4 2023; TTM through Dec 2023 was $5.0 million, a 89.9% decrease from a year earlier, with the FY2023 full-year figure at $5.0 million, down 89.9% from the prior year.
• Net Equity Issued and Repurchased for Q4 2023 stood at $2.8 million, up from -$138000.0 in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for DTIL reached as high as $47.9 million in Q2 2022 and fell as low as -$190000.0 in Q3 2022.
• Historically, Net Equity Issued and Repurchased has averaged $7.8 million across 3 years, with a median of $1.9 million in 2023.
• Across the five-year window, Net Equity Issued and Repurchased tumbled 102.26% in 2022 and climbed 27.37% in 2023, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $7.3 million in 2021, then plunged by 102.59% to -$190000.0 in 2022, then jumped by 1587.89% to $2.8 million in 2023.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $2.8 million in Q4 2023, -$138000.0 in Q3 2023, and $1.9 million in Q2 2023.